Denali Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Great. I think we'll get started with the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have Denali with us for the next session.
Briefly before we get started, I need to read a disclosure statement. So please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosure.
Questions & Answers
So with that, really pleased to have Ryan Watts, the CEO of Denali with us. Ryan, maybe just like an overarching question to start out, which is, I think, since Denali came public, we've seen a lot more companies come into the neurodegeneration space. I think everybody is not necessarily focused on the same targets or even focused on the same disease areas, but just broadly, as you think about the scope of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
